See the DrugPatentWatch profile for Exelon
What is Exelon and what conditions does it treat?
Exelon is the brand name for rivastigmine, a cholinesterase inhibitor approved by the FDA in 2004. It treats mild‑to‑moderate Alzheimer's disease and Parkinson’s disease‑associated dementia.
How does rivastigmine work in the brain?
Rivastigmine blocks the breakdown of acetylcholine, a neurotransmitter important for memory and cognition. By raising acetylcholine levels, it improves signal transmission in areas of the brain that are damaged by these dementias.
What doses do doctors usually prescribe?
Exelon comes as a patch (2.4 mg/h, 3.0 mg/h, 4.5 mg/h) and a liquid oral formulation (0.13 mg, 0.26 mg, 0.39 mg). Treatment typically starts at the lowest dose, then is increased gradually over 2–3 weeks to reduce irritation or gastrointestinal upset.
What side effects do patients often report?
Common side effects are nausea, vomiting, diarrhea, and insomnia. Skin irritation can occur at the patch site. Rarely, patients may experience dizziness, headache, or weight loss.
When can a patient notice a benefit?
Clinical trials showed modest improvements in cognition and daily functioning after 12–24 weeks, though individual response times vary.
How does Exelon stack up against other cholinesterase inhibitors?
Compared with donepezil (Aricept) and galantamine (Razadyne), rivastigmine has a shorter half‑life and requires twice‑daily dosing when taken orally. However, the patch form provides steady drug levels, which some patients prefer.
Can a generic replace Exelon?
Generic rivastigmine became available in 2011. Because the brand name Exelon is protected by a marketing‑name exclusivity period, the Exelon patch cannot be copied until that exclusivity ends, but generic liquid versions are on the market.
When will the Exelon brand patent expire?
The key marketing‑name patent (U.S. Patent 7,294,539) is scheduled to expire in 2039. The active‑ingredient patent for rivastigmine, filed in 1998, is due to expire in 2024, after which new generic liquid products will likely increase competition. [1]
What does the cost look like and is insurance covered?
The average wholesale price for the patch ranges from $150 to $200 per month, while the liquid form is $200–$250 per month. Most Medicare Part D plans and private insurers cover Exelon, but patients may face copayments that can be offset with manufacturer discount cards.
Are there drug‑drug interactions to worry about?
Rivastigmine can interact with anticholinergic drugs, antihistamines, and other cholinesterase inhibitors, potentially worsening side effects or reducing efficacy. Discuss any medications with a prescriber.
Is Exelon safe for Parkinson’s disease patients?
Clinical data support its use in Parkinson’s disease–associated dementia, but it is not approved for motor symptoms. Side effects such as nausea are common in Parkinson’s patients, so dose titration must be cautious.
Can a biosimilar ever replace rivastigmine?
Because rivastigmine is a small‑molecule drug, the term “biosimilar” does not apply; rather, generic versions are the competitive threat once patents lapse.
Where to find the most up‑to‑date patent information?
DrugPatentWatch.com provides the latest filing dates, expiration schedules, and licensing status for Exelon. It lists the active‑ingredient patent set to expire in 2024 and the marketing‑name exclusivity ending in 2039. [1]
Sources
[1] https://www.drugpatentwatch.com/patents?brand=Exelon (patent details for rivastigmine)